Impact of different iterative metal artifact reduction (iMAR) algorithms on PET/CT attenuation correction after port implementation.


Journal

European journal of radiology
ISSN: 1872-7727
Titre abrégé: Eur J Radiol
Pays: Ireland
ID NLM: 8106411

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 18 02 2020
revised: 29 04 2020
accepted: 07 05 2020
pubmed: 3 6 2020
medline: 20 1 2021
entrez: 3 6 2020
Statut: ppublish

Résumé

To evaluate the effect of various interactive metal artifact reduction (iMAR) algorithms on attenuation correction in the vicinity of port chambers in PET/CT. In this prospective study, 30 oncological patients (12 female, 18 male, mean age 59.6 ± 10.5y) with implanted port chambers undergoing 18F-FDG PET/CT were included. CT images were reconstructed with standard weighted filtered back projection (WFBP) and three different iMAR algorithms (hip, dental filling (DF) and pacemaker (PM)). PET attenuation correction was performed with all four CT datasets. SUVmean, SUVmax and HU measurements were performed in fat and muscle tissue in the vicinity of the port chamber at the location of the strongest bright and dark band artifacts. Differences between HU and SUV values across all CT- and PET-images were investigated using a paired t-test. Bonferroni correction was used to prevent alpha-error accumulation (p < 0.008). In comparison to WFBP (fat: 94.2 ± 53.9 HU, muscle: 197.6 ± 49.2 HU) all three iMAR algorithms led to a decrease of HU in bright band artifacts. iMAR-DF led to a decrease of 159.2 % (fat: -51.9 ± 58.5 HU, muscle: 94.5 ± 55.3 HU), iMAR-hip of 138.3 % (fat: -30.3 ± 58.5, muscle: 70.4 ± 28.8) and iMAR-PM of 122.3 % (fat: -21.2 ± 47.2 HU, muscle: 72.5 ± 25.1 HU; for all p < 0.008). There was no significant effect of iMAR on SUV measurements in comparison to WFBP. iMAR leads to a significant change of HU values in artifacts caused by port catheter chambers in comparison to WFBP. However, no significant differences in attenuation correction and consecutive changes in SUV measurements can be observed.

Identifiants

pubmed: 32485336
pii: S0720-048X(20)30254-0
doi: 10.1016/j.ejrad.2020.109065
pii:
doi:

Substances chimiques

Metals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109065

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors declare that there are no potential conflict of interest. Benedikt M. Schaarschmidt is a stockholder for Bayer AG, General Electric, Siemens AG, Siemens Healthineers AG, TEVA Pharmaceuticals.

Auteurs

Ole Martin (O)

University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany.

Johannes Boos (J)

University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany. Electronic address: Ole.Martin@med.uni-duesseldorf.de.

Joel Aissa (J)

University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany.

Christian Vay (C)

University Dusseldorf, Medical Faculty, Clinic for General, Visceral and Pediatric Surgery, D-40225 Dusseldorf, Germany.

Philipp Heusch (P)

University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany.

Susanne Gaspers (S)

University Dusseldorf, Medical Faculty, Clinic for Nuclear Medicine, D-40225 Dusseldorf, Germany.

Christina Antke (C)

University Dusseldorf, Medical Faculty, Clinic for Nuclear Medicine, D-40225 Dusseldorf, Germany.

Martin Sedlmair (M)

Department of Computed Tomography, Siemens Healthineers GmH, Forchheim, Germany.

Gerald Antoch (G)

University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany.

Benedikt M Schaarschmidt (BM)

University Dusseldorf, Medical Faculty, Department of Diagnostic and Interventional Radiology, D-40225 Dusseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH